X4 PHARMACEUTICALS, INC (XFOR) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2023-12-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2023-12-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2023-12-31..
Borrowing debt
Overview →Financial period ending 2023-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2023-12-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2023-12-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2023-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 54.57M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 147.26M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | (m) | (m) | $0.00 | $54.57M | (m) | (m) | $147.26M | (m) |
| 2023-09-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | $173.29M | (m) |
| 2023-06-30 | (m) | (m) | $764.00K | (m) | (m) | (m) | $173.40M | (m) |
| 2023-03-31 | (m) | (m) | $554.00K | (m) | (m) | (m) | $124.41M | (m) |
| 2022-12-31 | (m) | (m) | $1.31M | $32.30M | (m) | (m) | $155.59M | (m) |
| 2022-09-30 | (m) | (m) | $14.62M | (m) | (m) | (m) | $113.41M | (m) |
| 2022-06-30 | (m) | (m) | $8.61M | (m) | (m) | (m) | $81.02M | (m) |
| 2022-03-31 | (m) | (m) | $3.42M | (m) | (m) | (m) | $99.63M | (m) |
| 2021-12-31 | (m) | (m) | $795.00K | $33.14M | (m) | (m) | $117.18M | (m) |
| 2021-09-30 | (m) | (m) | $693.00K | (m) | (m) | (m) | $120.52M | (m) |
| 2020-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | $122.87M | (m) |
| 2019-12-31 | (m) | (m) | $0.00 | $20.00M | (m) | (m) | $160.70M | (m) |
| 2019-09-30 | (m) | (m) | $0.00 | $20.00M | (m) | (m) | $109.54M | (m) |
| 2019-06-30 | (m) | (m) | $4.15M | $22.20M | (m) | (m) | $133.51M | (m) |
| 2019-03-31 | (m) | (m) | $5.30M | $14.25M | (m) | (m) | $62.55M | (m) |
| 2018-12-31 | (m) | (m) | $1.69M | $8.31M | (m) | (m) | $9.94M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |